Literature DB >> 16416174

The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome.

J Alexander Cole1, Jason M Yeaw, Jennifer A Cutone, Braden Kuo, Zhiping Huang, David L Earnest, Alexander M Walker.   

Abstract

Rates of abdominopelvic surgery, with a particular focus on gallbladder procedures, were measured in patients with irritable bowel syndrome (IBS) (n = 108,936) and compared with those in a general population sample (n = 223,082). The patient sample was selected from persons who were members of a managed care organization during the years 1995-2000. Medical records from a randomly selected subset of IBS patients were reviewed to confirm the diagnosis. Crude and standardized rates and adjusted rate ratios for surgery were calculated. The incidence of abdominopelvic surgery, excluding gallbladder procedures, was 87% higher in patients with IBS than that for the general population. The incidence of gallbladder surgery was threefold higher in IBS patients than the general population. Patients with IBS have an increased risk for abdominopelvic and gallbladder surgery and, thus, an associated risk for experiencing morbidity and mortality associated with these surgical procedures.

Entities:  

Mesh:

Year:  2005        PMID: 16416174     DOI: 10.1007/s10620-005-3047-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

Review 2.  The irritable bowel syndrome.

Authors:  B J Horwitz; R S Fisher
Journal:  N Engl J Med       Date:  2001-06-14       Impact factor: 91.245

3.  Evidence-based position statement on the management of irritable bowel syndrome in North America.

Authors: 
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

Review 4.  Irritable bowel syndrome: definition, diagnosis and epidemiology.

Authors:  N J Talley
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  1999-10

5.  Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.

Authors:  James Fidelholtz; William Smith; James Rawls; Yingqi Shi; Anna Zack; Peter Rüegg; Martin Lefkowitz
Journal:  Am J Gastroenterol       Date:  2002-05       Impact factor: 10.864

6.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

7.  Irritable bowel syndrome and surgery: a multivariable analysis.

Authors:  George F Longstreth; Janis F Yao
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

8.  A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Authors:  J Novick; P Miner; R Krause; K Glebas; H Bliesath; G Ligozio; P Rüegg; M Lefkowitz
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171

9.  Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization.

Authors:  N J Talley; A R Zinsmeister; L J Melton
Journal:  Am J Epidemiol       Date:  1995-07-01       Impact factor: 4.897

10.  Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population.

Authors:  L Quam; L B Ellis; P Venus; J Clouse; C G Taylor; S Leatherman
Journal:  Med Care       Date:  1993-06       Impact factor: 2.983

View more
  15 in total

1.  Acute abdominal pain in irritable bowel syndrome patients: not always an acute exacerbation.

Authors:  Vui Heng Chong; Chean Leung Chong
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.199

2.  Avoiding unnecessary surgery in irritable bowel syndrome.

Authors:  George F Longstreth
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

3.  Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study.

Authors:  M A McNally; G R Locke; A R Zinsmeister; C D Schleck; J Peterson; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2008-08-01       Impact factor: 8.171

4.  Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Stephen J Vanner; William G Paterson; Ron J Bridges
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

5.  The continuing dilemma of chronic appendicitis.

Authors:  Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

Review 6.  Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments.

Authors:  Lucinda A Harris; Stephanie Hansel; John DiBaise; Michael D Crowell
Journal:  Curr Gastroenterol Rep       Date:  2006-08

7.  Improved health-related quality of life after surgical management of severe refractory constipation-dominant irritable bowel syndrome.

Authors:  Jennifer Y Lam; Biniam Kidane; Farouq Manji; Brian M Taylor
Journal:  Int Surg       Date:  2015-01

Review 8.  Fibromyalgia: an update and immunological aspects.

Authors:  Eduardo S Paiva; Evelin Diana Goldenberg Mariano da Costa; Morton Scheinberg
Journal:  Curr Pain Headache Rep       Date:  2008-10

9.  An observational study of cholecystectomy in patients receiving tegaserod.

Authors:  Allen Brinker; Stephanie D Schech; Margaret Burgess; Mark Avigan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Patients With Somatoform Disorders Are Prone to Expensive and Potentially Harmful Medical Procedures—Results of a Retrospective Cohort Study Over 15 Years.

Authors:  Antonius Schneider; Ewan Donnachie; Stephan Zipfel; Paul Enck
Journal:  Dtsch Arztebl Int       Date:  2021-06-25       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.